Elanco Strengthens Companion Animal Portfolio

Following the launch of Elanco Companion Animal Health in the UK in October 2010 and Elanco’s recent acquisition of Janssen Animal Health, its parent company, Eli Lilly and Company, is continuing its investment in the animal health industry, particularly in the companion health and dairy sectors. Elanco is demonstrating its commitment to the veterinary industry by focusing on innovation, support and value , with the launch of three exciting new products during 2011, which will offer new therapeutic options and potential income streams for veterinary practices. This follows the launch of the first oral flea treatment for dogs, Comfortis®, in April 2011 which combines a rapid ‘kill rate’ and a month’s protection against fleas. Already ranked as the number one recommended prescription flea medication for dogs in the USA, the palatable beef-flavoured chewable tablet features a unique molecule, spinosad, as its active ingredient and will enable veterinary practices to offer their clients a unique product that is only available through the veterinary channel to help protect sales of flea products. The company has also invested in its key account management team and there are now 12 dedicated companion animal key account managers who are trained to offer excellent first line product support. This is backed up by a technical helpline for all companion animal product enquiries from veterinary professionals, a team of technical advisors who are available to discuss difficult cases and a range of support material to offer advice to pet owners. In addition to product support, Elanco will also be expanding its ‘Elanco Elite Rewards’ discount scheme in early 2012 which will enable qualifying practices to earn discounts across the company’s product range. The Elanco Companion Animal division is headed by business unit manager, Tina Hunt. She heads up a team of 20, including nine Janssen employees who moved to Elanco following the acquisition, and reports in to Mike Brown, country director of U.K. and Ireland. “Our acquisition of Janssen will strengthen our presence in the companion animal sector, which will be further boosted with the launch of three innovative new products in the next year,” comments Mike Brown, country director of U.K. and Ireland at Elanco Animal Health. “This investment is great news in a difficult climate, when many companies are looking to sell off their animal health businesses or reduce their R&D investment. It will also build on our goal of enabling veterinary professionals to help pets live longer, healthier and higher quality lives.” Elanco’s expertise focuses on four key areas: dermatology, parasitology, anaesthesia and pain relief and equine. Its product range includes Comfortis, Surolan, Surosolve, Dexdomitor, Domosedan Gel, Danilon and Duvaxyn, Elanco is a global innovation-driven company that develops and markets products to improve animal health and food-animal production in more than 75 countries. It employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading innovation-driven pharmaceutical corporation. Additional information on Elanco is available at www.elancopet.com and the company can be contacted via email: [email protected].

More from

• West Midlands communications agency celebrates quartet of award nominations for work in veterinary sector
• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits